MedTrace Logo

Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo

NCT02315508 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2016-03-31

No results posted yet for this study

Summary

This study aims to demonstrate that the new medicine AUT00063 is effective and safe in the treatment of tinnitus.

Conditions

  • Tinnitus, Subjective

Interventions

DRUG

AUT00063

800 mg orally, once a day, for 4 weeks

DRUG

Placebo

orally, once a day, for 4 weeks

Sponsors & Collaborators

  • University of Nottingham

    collaborator OTHER

  • Autifony Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Jaydip Ray, MD · Sheffield Teaching Hospitals NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315508 on ClinicalTrials.gov